Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus

Gastroenterology

Volumn 138, Issue 7, 2010, Pages 2260-2266

  Nguyen, Dang M ^a   Richardson, Peter ^a   El Serag, Hashem B ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Epidemiology; Gastroesophageal Reflux Disease; VA

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CIMETIDINE; DICLOFENAC; ESOMEPRAZOLE; ETODOLAC; FAMOTIDINE; FENOPROFEN; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LANSOPRAZOLE; MECLOFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROFECOXIB; SULINDAC; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SOCIAL STATUS;

EID: 77952837521     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.02.045     Document Type: Article

References (22)

1. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
2. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129 (2005) 1825-1831
3. Phillips R.W., and Wong R.K. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 20 (1991) 791-816
4. Spechler S.J. The columnar-lined esophagus. History, terminology, and clinical issues. Gastroenterol Clin North Am 26 (1997) 455-466
5. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 27 (2003) 999-1008
6. Blais L., Desgagne A., and Lelorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160 (2000) 2363-2368
7. Karp I., Behlouli H., Lelorier J., et al. Statins and cancer risk. Am J Med 121 (2008) 302-309
8. Ogunwobi O.O., and Beales I.L. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 103 (2008) 825-837
9. Garcia Rodriguez L.A., Lagergren J., and Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55 (2006) 1538-1544
10. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
11. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004) 1877-1883
12. Hillman L.C., Chiragakis L., Shadbolt B., et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180 (2004) 387-391
13. Hillman L.C., Chiragakis L., Shadbolt B., et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 27 (2008) 321-326
14. Nguyen D.M., El-Serag H.B., Henderson L., et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 7 (2009) 1299-1304
15. Vaughan T.L., Dong L.M., Blount P.L., et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6 (2005) 945-952
16. Prentice R., and Brestlow N. Retrospective studies and failure time models. Biometrika 65 (1978) 153-158
17. Morris C.D., Armstrong G.R., Bigley G., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96 (2001) 990-996
18. Tsibouris P., Hendrickse M.T., and Isaacs P.E. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther 20 (2004) 645-655
19. van Vliet E.P., Eijkemans M.J., Steyerberg E.W., et al. The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands. Br J Cancer 95 (2006) 1180-1185
20. El-Serag H.B., Johnson M.L., Hachem C., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136 (2009) 1601-1608
21. Morgan R.O., Petersen L.A., Hasche J.C., et al. VHA pharmacy use in veterans with Medicare drug coverage. Am J Manag Care 15 (2009) e1-e8
22. El-Serag H.B., Wieman M., and Richardson P. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther 27 (2008) 1293-1299